Pharma falls on Trumps comments, analysts say impact unlikely

Shares of Sun Pharma, Dr Reddy's Labs and Cadila were down dragging the index almost 1 percent from previous close. Major Indian pharma companies earn around 15-50 percent revenue from the US market.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap Tech Control

Budget 2017

Presented By:

DAYS hours minutes
Presented by :

Co-Presenting Sponsor :

Associate Sponsors :

Co-Presenting Sponsor :

Associate Sponsors :

Home » News » Buzzing Stocks

Jan 12, 2017, 07.19 PM | Source: Moneycontrol.com

Pharma falls on Trump's comments, analysts say impact unlikely

Shares of Sun Pharma, Dr Reddy's Labs and Cadila were down dragging the index almost 1 percent from previous close. Major Indian pharma companies earn around 15-50 percent revenue from the US market.

Like this story, share it with millions of investors on M3

Pharma falls on Trumps comments, analysts say impact unlikely

Shares of Sun Pharma, Dr Reddy's Labs and Cadila were down dragging the index almost 1 percent from previous close. Major Indian pharma companies earn around 15-50 percent revenue from the US market.

Post Your Comments

Share Cancel

| 8 Comments
Shares of pharma companies were under pressure following US President-Elect Donald Trump's comments on drug pricing and foreign manufacturing. Trump said that the US will create new drug-bidding procedure.

Shares of Sun Pharma , Dr Reddy's Labs and Cadila were down dragging the index almost 1 percent from previous close. Major Indian pharma companies earn around 15-50 percent revenue from the US market.

US President-elect Donald Trump on Wednesday said pharmaceutical companies are "getting away with murder" in what they charge the government for medicines, and promised that would change, sending drugs stocks sharply lower.

Trump's campaign platform included allowing the Medicare healthcare program to negotiate with pharmaceutical companies, which the law currently prohibits. He has also discussed making it easier to import drugs at cheaper prices.

Trump said he plans to repeal the Affordable Care Act, or Obamacare, and replace it at about the same time.

However, analysts say that Indian companies are unlikely to be impacted due to pressure on bringing down prices of innovative drugs. They say Indian Pharma companies provide low cost generic drugs, keep prices of drugs low in the US. But what could hurt Indian companies are issues such as Medicare negotiating, bidding for government contracts.

Kiran Mazumdar Shaw, CMD of Biocon also agrees any negative impact on generic suppliers here is ruled out. She said she completely agrees with Trump's view but doesn't see his views affecting Indian pharma. “I don’t think these are going to be big issues; if Indian pharma companies are supplying these products to the US markets and if there are no US suppliers, which is mostly the case, this doesn’t affect the Indian pharma companies,” she said.

Buy, Hold, Sell ? Hear it first on M3
Pharma falls on Trumps comments, analysts say impact unlikely

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login